A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Mallia Therapeutics & Northway Biotech partner to manufacture soluble CD83 protein for hair loss treatment: Erlangen, Germany Wednesday, February 5, 2025, 15:00 Hrs [IST] Mallia T ...

HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...